Carbamazepine induced transient monoclonal gammopathy and immunodeficiency

Allergologia et Immunopathologia

Volumn 32, Issue 2, 2004, Pages 86-88

  Moreno Ancillo, A ^a   Cosmes Martin P M ^a   Dominguez Noche C ^a   Martin Nunez G ^a   Fernandez Galan M A ^a   Lopez Lopez R ^a   Gonzalez Hurtado J A ^a   Gil Adrados, A C ^b  

^a HOSPITAL VIRGEN DEL PUERTO   (Spain)

^b Centro de Salud La Estacion   (Spain)

Author keywords

Carbamazepine; IgA deficiency; IgG kappa paraproteinemia; IgM deficiency; Immunodeficiency; Monoclonal gammopathy

Indexed keywords

ANTINUCLEAR ANTIBODY; CARBAMAZEPINE; IMMUNOGLOBULIN A; IMMUNOGLOBULIN KAPPA CHAIN; IMMUNOGLOBULIN M; PARAPROTEIN;

ADULT; ARTHRALGIA; ARTICLE; B CELL LYMPHOMA; BONE MARROW EXAMINATION; CASE REPORT; CLINICAL FEATURE; DIFFERENTIAL DIAGNOSIS; DRUG INDUCED DISEASE; DRUG WITHDRAWAL; EPILEPSY; FEMALE; HUMAN; IMMUNE DEFICIENCY; MALAISE; MONOCLONAL IMMUNOGLOBULINEMIA; MYELOMA; PARAPROTEINEMIA; RISK FACTOR; SKIN TEST; SYMPTOM;

EID: 3042641347     PISSN: 03010546     EISSN: None     Source Type: Journal    
DOI: 10.1157/13059850     Document Type: Article

References (16)

1. th edition). J.P. Lippincott Company, (Philadelphia), 1993; p. 395-530.
2. Elstner S, Sperling W. The carbamazepine hypersensitivity syndrome. Differential diagnosis and a representative case history. Fortschr Neurol Psychiatr 2000;68(4):188-92.
3. Tohen M, Castillo J, Baldessarini RJ, Zarate C Jr, Kando JC. Blood dyscrasias with carbamazepine and valproate: a pharmaco-epidemiological study of 2,228 patients at risk. Am J Psychiatry 1995;152(3):413-8.
4. Basaran N, Hincal F, Kansu E, Ciger A. Humoral and cellular immune parameters in untreated and phenytoin- or carbamazepine-treated epileptic patients. Int J Immunopharmacol 1994;16:1071-7.
5. Marcolini M, Gatti G, Ippoliti G, Lombardi M, Crema A, Zocchi MT, De Ponti F, Lecchini S, Frigo GM. Effect of chronic anticonvulsant monotherapy on lymphocyte subpopulations in adult epileptic patients. Hum Toxicol 1985;4(2):147-57.
6. Pacifi R, Paris L, Di Carlo S, Pichini S, Zuccaro P. Immunologic aspects of carbamazepine treatment in epileptic patients. Epilepsia, 1991;32(1):122-7.
7. Gilhus NE, Lea T. Carbamazepine: effects on IgG subclasses in epileptic patients. Epilepsia 1988;29(3):317-20.
8. D'Incan M, Mouillet ML, Roger H, Ferrier MC, Buono JP, Dechelotte P, Bignon YJ, Souteyrand P. Cutaneous pseudolymphoma caused by carbamazepine. Ann Dermatol Venereol 1998;125(1):52-5.
9. Kyle RA, Rajkumar SV. Monoclonal gammopathies of undetermined significance. Hematol Oncol Clin North Am 1999;13(6):1181-202.
10. Matzner Y, Polliack A. Monoclonal gammopathy and subsequent multiple myeloma in a patient on chronic diphenylhydantoin therapy. Isr J Med Sci 1978;14(12):1265-7.
11. Asai S, Miyachi H, Kobayashi H, Hotta T, Ando Y. Smoldering myeloma associated with zonisamide treatment. Intern Med 2002;41(2):138-41.
12. Aymard JP, Lederlin P, Witz F, Colomb JN, Faure G, Guerci O, Herbeuval R. Multiple myeloma after phenytoin therapy. Scand J Haematol 1981;26(4):330-2.
13. Madrigal Diez V, Alonso Palacio J, Arteaga Manjón R, Herranz Fernández JL. "Carbamazepine serious intolerance in intersticial pneumonia, fever, exanthema and immunoglobulin deficiency". An Esp Pediatr 1993;38(2):1990-2.
14. Spickett GP, Gompels MM, Saunders PW. Hypogammaglobulinaemia with absent B lymphocytes and agranulocytosis after carbamazepine treatment. J Neurol Neurosurg Psychiatry 1996;60(4):459.
15. Boissier MC, Sansonetti P, Dupont B, Lapresle C. Major intolerance to carbamazepine. Acquired immunodepression or allergy. Sem Hop 1983;59(43):2989-90.
16. Voutsinas D, Foudoulaki L, Sofroniadou K, Galanakis N. Visceral leishmaniasis in a patient with acquired hypogamma-globulinemia. Eur J Intern Med 2001;12(2):127-9.